Phase 2a Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Repeated Administrations Over 4 Weeks of the Hepcidin Antagonist PRS-080#022-DP in Anemic Chronic Kidney Disease Patients Undergoing Hemodialysis
Phase of Trial: Phase II
Latest Information Update: 22 Nov 2018
At a glance
- Drugs PRS 080 (Primary)
- Indications Iron deficiency anaemia
- Focus Adverse reactions
- Sponsors Pieris Pharmaceuticals
- 09 Nov 2018 Planned End Date changed from 31 Jul 2018 to 30 Jun 2019.
- 09 Nov 2018 Planned primary completion date changed from 30 Apr 2018 to 30 Mar 2019.
- 07 Nov 2018 According to a Pharmaceuticals media release, results from the study are expected in the second half of 2019.